Screener
Syndax Pharmaceuticals SNDX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized; 88,543,881 and 87,405,979 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
| Additional paid-in capital | 1,590,855 | 1,570,749 |
| Accumulated other comprehensive gain | 11 | 452 |
| Accumulated deficit | (1,549,253) | (1,506,580) |
| Total stockholders’ equity | 41,622 | 64,630 |
| Total liabilities and stockholders’ equity | $472,668 | $529,706 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's retained earnings?
- Syndax Pharmaceuticals (SNDX) reported retained earnings of -$1.55B in Q1 2026.
- How has Syndax Pharmaceuticals's retained earnings changed year-over-year?
- Syndax Pharmaceuticals's retained earnings decreased by 18.6% year-over-year, from -$1.31B to -$1.55B.
- What is the long-term trend for Syndax Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's retained earnings has grown at a 21.5% compound annual growth rate (CAGR), from -$568.63M to -$1.51B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Syndax Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude